Supplemental Data Set

<b>Characteristics of the </b><b>c</b><b>ohort </b><b>u</b><b>nderpinning this </b><b>c</b><b>ross-</b><b>s</b><b>ectional </b><b>s</b><b>tudy</b><b>Methods</b>Part A: Metabolomics profiling and data preprocessingPart B: Drug deconfounding analysisPart C: Transcriptomics profiling and data preprocessing<b>Table </b><b>S</b><b>1. </b>Diagnosis and pharmacological treatment of 19 HIV-positive individuals with cardiovascular disease<b>Table </b><b>S2</b><b>.</b><b> </b>Classification of metabolomic features as dysmetabolic, escalation, de-escalation and CVD<b>Table </b><b>S3</b><b>. </b>Classification of transcriptome features as dysmetabolic, escalation, de-escalation and CVD<b>Table </b><b>S4.</b> Classification of metabolomic features as dysmetabolic, escalation, de-escalation and CVD as well as comparison based on the cardiometabolic disease spectrum<b>Table </b><b>S5. </b>Pathway enrichment analysis of metabolome markers in the cardiometabolic disease spectrum in people living with HIV<b>Fig</b><b>.</b><b> S1</b><b> </b>Operational classification of metabolome features from the perspective of CVD pathology<b>Fig. S</b><b>2 </b>Methodology employed for the classification of transcriptome features in the cross-sectional study<b>Fig. S</b><b>3 </b>Transcriptome features associated with CVD and its dysmetabolic pre-morbidities<b>Fig. S</b><b>4 </b>Functional enrichment analysis of transcriptome markers